Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of CHG regimen (low-dose cytarabine,
homoharringtonine with G-CSF priming) to decitabine in the treatment of higher-risk
myelodysplastic syndromes(MDS).